“…The endocannabinoid system has shown promise as a target for seizure control, but there are conflicting reports about the efficacy of cannabinoid (CB) receptor targeting compounds in suppressing seizures (Rosenberg et al, 2017 ). One of the most promising candidates are CB1 receptor agonists, which exert anticonvulsant effects against generalized tonic seizures in the maximal electroshock test (Luszczki et al, 2006 ; Florek-Luszczki et al, 2014b ; Tutka et al, 2018 ), but produce mixed effects against generalized seizures evoked by pentylenetetrazole (Bahremand et al, 2008a ; Andres-Mach et al, 2012 ; Vilela et al, 2013 ; Aghaei et al, 2015 ; Huizenga et al, 2017 ) and limbic seizures in the kainic acid model (Bojnik et al, 2012 ; Shubina et al, 2015 ). These models are characterized by different types of seizures: the former by tonic seizures that critically rely on brainstem networks (Merrill et al, 2003 , 2005 ), and the later by limbic seizures that critically rely on forebrain networks (Browning et al, 1993 ).…”